Compare SPWH & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPWH | KLRS |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1M | 46.0M |
| IPO Year | 2014 | N/A |
| Metric | SPWH | KLRS |
|---|---|---|
| Price | $1.18 | $10.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $2.95 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 350.5K | 54.1K |
| Earning Date | 03-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,197,633,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $0.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $2.14 |
| 52 Week High | $4.33 | $11.90 |
| Indicator | SPWH | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 34.22 | 62.78 |
| Support Level | $1.16 | $8.08 |
| Resistance Level | $1.35 | $10.28 |
| Average True Range (ATR) | 0.09 | 0.96 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 18.33 | 95.95 |
Sportsman's Warehouse Holdings Inc together with its subsidiaries operates as an outdoor sporting goods retailer. It provides a one-stop shopping experience that equips customers with the right quality, brand name hunting, shooting, fishing, and camping gear to maximize enjoyment of the outdoors. The company offers products in the categories of Camping, Apparel, Fishing, Footwear, Hunting and shooting, and Optics, Electronics, Accessories, and Other products. It provides products such as Backpacks, Jackets, Camp essentials, Hiking boots, GPS devices, ATV accessories and Fishing rods, among others.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.